Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluphenazine SCHEMBL19221 | 1.00 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL5072860 | 1.00 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL29354183 | 1.00 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL7194252 | 0.99 | LMNA (0.98) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL41635 | 0.99 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL30390918 | 0.99 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL41634 | 0.99 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL1496274 | 0.99 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL2560022 | 0.99 | LMNA (1.00) | LMNAMAPTCYP3A4MAPK1USP2 | |
| Fluphenazine SCHEMBL28642082 | 0.99 | LMNA (0.98) | LMNAMAPTCYP3A4MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3194027-B1 | COMPOSITIONS FOR USE IN TREATING PSYCHOTIC DISORDERS | SOUND PHARMACEUTICALS INCORPORATED (US) | 2026-02-11 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4049681-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR AND USES THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2026-01-07 | — | — | EP | claimed |
| EP-3334725-B1 | BROMODOMAIN AND EXTRA TERMINAL (BET) INHIBITOR AND A PROTEIN PHOSPHATASE 2A (PP2A) ACTIVATOR FOR TREATING BET INHIBITOR RESISTANT CANCER | DANA FARBER CANCER INST INC (US) | 2025-04-23 | — | — | EP | claimed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| EP-3638673-B9 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-20 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| EP-3638673-B1 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | claimed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | claimed |
| EP-3529229-B1 | POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF | SYNEURX INT TAIWAN CORP (TW) | 2024-04-17 | — | — | EP | claimed |
| EP-3125893-B1 | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS | INTRA CELLULAR THERAPIES INC (US) | 2023-09-20 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3824900-B1 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | AMICUS THERAPEUTICS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12552736-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260014162-A1 | REHYDRATION COMPOSITION AND METHOD OF USE | YourLifeRx, Inc., d/b/a Daywel, Inc. (US) | 2026-01-15 | — | — | US | disclosed |
| US-11358926-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3980401-A1 | PURINE DERIVATIVES, AS NR2B NEGATIVE MODULATORS AND THE USE THEREOF AS MEDICAMENT, IN PARTICULAR FOR TREATING DEPRESSIVE DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2022-04-13 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552736-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | GBA1, GALC, GBA2 | DRD2 1113/4885LMNA 382/4885MAPT 356/4885 |
| US-20260014162-A1 | REHYDRATION COMPOSITION AND METHOD OF USE | AQP1, SLC5A1, SLC2A1 | DRD2 1199/4885LMNA 3357/4885MAPT 3012/4885 |
| US-11358926-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | GBA1, GALC, GAA | DRD2 3119/4885LMNA 290/4885MAPT 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.